GRAIL's financial position is reinforced by $435 million in new funding, including strategic backing from Samsung for ...
Data from this study will be submitted to the U.S. Food and Drug Administration (FDA) as part of the Galleri premarket approval (PMA) application ... The live webcast and recorded replay are open to ...
Xvivo Perfusion AB (publ) ( OTCPK:XVIPY) Q3 2025 Earnings Call October 23, 2025 8:00 AM EDT [Operator Instructions] The next question comes from Simon Larsson from Danske Bank.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback